Acquisitions And Asian Expansion Will Broaden Healthcare Horizons

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

22 Aug 24

Updated

22 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-41.1%

7D

2.7%

Loading

1Y

-41.1%

7D

2.7%

You can edit this narrative until Nov 23 7:10 AM. Then, changes will post as Updates.

Author's Valuation

US$124.147.8% undervalued

AnalystConsensusTarget Fair Value

Shared on 22 Nov 25

Fair value Decreased 2.80%

TFX: Future Diabetes Trial Progress Will Drive Upside Despite Margin Pressures

Teleflex's analyst price target has been revised downward by $3.57 to $124.14. Analysts cite modest reductions in expected profit margins and growth as driving factors for the update.

Shared on 07 Nov 25

Fair value Decreased 3.70%

TFX: Future Advances In Diabetes Trials And Asian Market Expansion Will Drive Upside

Analysts have revised their price target for Teleflex downward from $132.63 to $127.71. They cite higher discount rates and softer revenue growth projections, despite improved profit margins and a lower expected future price-to-earnings ratio.

Shared on 29 Aug 25

Fair value Decreased 5.34%

Despite a near-term upside from strong Q2 results, Teleflex’s consensus price target has been revised down to $132.62 due to persistently modest organic growth and muted EPS increases, with valuation already reflecting current expectations despite anticipated second-half acceleration. Analyst Commentary Strong Q2 results provided near-term upside surprise.

Shared on 07 May 25

Fair value Decreased 24%

Shared on 30 Apr 25

Fair value Increased 16%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

Fair value Decreased 6.51%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 1.80%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Increased 7.33%

AnalystConsensusTarget has decreased revenue growth from 5.2% to 2.5% and decreased future PE multiple from 22.2x to 16.8x.

AnalystConsensusTarget Fair Value

US$124.14

7.8% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

7.30%

Medical Equipment revenue growth rate

8.27%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

9.01%

Calculation

US$639.83m

Earnings '28

x

9.58x

PE Ratio '28

=

US$6.13b

Market Cap '28

US$6.13b

Market Cap '28

/

38.27m

No. shares '28

=

US$160.13

Share Price '28

US$160.13 Share Price '28

Discounted to 2025 @ 9.11% p.a.

=

US$123.27

Fair Value '25